News

GO2 Foundation Leads Study to Improve Participation of Black Communities in Lung Cancer Clinical Trials
March 04, 2021
NEWS PROVIDED BY GO2 Foundation for Lung Cancer  SAN CARLOS, Calif. and WASHINGTON, March 4, 2021 /PRNewswire/ -- GO2 Foundation for Lung Cancer (GO2 Foundation) announced its leadership in the launch of an important…
ERT Imaging Accelerates Ground-Breaking Research to Improve the Development of Oncology and CNS Treatments
March 01, 2021
Blue Earth Diagnostics utilizing ERT imaging solution to evaluate a novel imaging agent for potential use to inform brain metastases disease management
Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging
February 17, 2021
LONDON, Feb. 17, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, today announces a research collaboration with Essen University Hospital to examine…
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming 2021 ASCO Genitourinary Cancers Symposium (ASCO GU)
February 08, 2021
Global survey presented at the Digital Liver Cancer Summit 2021 reveals heavy toll of COVID-19 first wave on liver cancer care
February 05, 2021
Digital Liver Cancer Summit 2021: A global survey assessing the impact of COVID-19 on liver cancer has revealed delays in the screening, diagnosis, and treatment of the disease, with experts issuing stark warnings on liver cancer survival rates.
CIONewsLogo 2021
CIO 2021 Meeting News
February 02, 2021
Join us in Miami for the practical IO meeting of the year!
Dr Holden
Novel Embolic Device Used for Arterial and Venous Tumor Treatments
February 01, 2021
GPX Embolic Device Showcased at Leipzig Interventional Course (LINC) for Interventional Oncology Embolizations
SonALAsense Pioneers Sonodynamic Therapy, a First-in-Class Noninvasive Therapy for Lethal Brain Cancers; Enters Into a Collaboration and License Agreement With Insightec and a Collaboration Agreement with Ivy Brain Tumor Center to Conduct the First-in-Man
December 31, 2020
Non-Invasive Drug-Device Treatment Aims to Target Brain Cancers Selectively, Turning them from Lethal Diseases into Manageable Conditions: Led by Experts with Decades of Experience Developing and Commercializing Drug-Device Systems in Photodynamic…
New Embolic Device Used in Interventional Oncology for Highly Targeted Tumor Treatment
November 23, 2020
Novel Interventional Oncology Embolization Device Successfully Used in Trans-Radial Access Procedures for Tumor Devascularization
ESMO ASIA Congress 2020 | CStone Pharmaceuticals announces the results of GEMSTONE-302, Sugemalimab has the potential to provide a new treatment option for patients with advanced NSCLC
November 23, 2020
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today announced that positive clinical data based on a…
Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020
November 23, 2020
ORIENT-32 is the first randomized Phase 3 study reporting the efficacy and safety of an anti-PD-1 antibody-based combination therapy versus sorafenib as the first-line treatment in patients with advanced unresectable hepatocellular carcinoma (HCC).
Back to Top